Over the last few years, an increased awarenes of endocrine disrupting chemicals (EDCs) 
Reports in the last few years describing apparent increases in developmental, reproductive, or behavioral abnormalities as well as certain types of cancer in wildlife (1) (2) (3) (4) or humans (5-7) have resulted in a worldwide intensification of research efforts to characterize endocrine disrupting chemicals (EDCs). Even though there are few, but significant, examples of a direct link from exposure to an EDC to adverse effects in humans (8) (9) (10) , many of the mechanistic pathways mediating the deleterious effects resulting from EDC exposure ofwildlife and laboratory animals have been elucidated (1, (11) (12) (13) (14) (15) . As a result, screening for endocrine activity has recently been mandated-in the United States by the Food Quality Protection Act (Public Law 104-170) and the Safe Drinking Water Act amendments (Public Law 104-182) of 1996. Recent workshops have darified the definition of EDCs (16) , identified research needs (16) (17) (18) , and reviewed potential EDC screening methods (19) (20) (21) (22) . While it is clear that a spectrum of in vivo screens may be required to characterize a compound as an EDC that can cause adverse effects in exposed organisms, in vitro assays are required to define the molecular mechanisms responsible for these effects. The enormous task of screening tens of thousands of natural and man-made chemicals for EDC activity suggests that in vitro assays are the most practical means to quickly identify compounds which may have the potential to cause adverse endocrine disruption effects in whole organisms.
Many of the adverse effects and biochemical mechanisms of action of EDCs identified over the last 20 years have been attributed to environmental estrogens (11, (23) (24) (25) (26) (27) (28) (29) (30) . These substances mimic or block the activity of natural estrogens by specifically binding to the estrogen receptor (ER) nuclear protein, resulting in the transcriptional control of a variety of genes in target cells. ER-a is a 66 kDa transcription factor that regulates expression of genes involved in tissue growth and differentiation, functioning in diverse target tissues including reproductive, skeletal, cardiovascular, and mammary tumors (31, 32) . ER and other steroid hormone-receptors are activated by one or more endogenous ligands that bind with high affinity to the receptor's carboxy-terminal hormone binding domain. Ligand binding initiates a number of changes in the receptor including altered conformation, dimerization, and changes in interaction with other proteins (33) . The (34) (35) (36) . Competitive (21, 41) .
Several methods are used to follow ligand-ER binding interactions (20, 22, 42, 43 Figure  2 . In this experiment, a constant amount of FES1 was titrated with increasing concentrations of hrER-ac. At each receptor concentration, the FP value was measured and used to calculate the amount of bound (FES1-hrER-ax) and free hrER-ax. The FES1-hrER-a interaction had a Kd of 0.3 nM and exhibited positive cooperativity. These results compare favorably to the affinity obtained for radioactive E2 and native ER, and their observed cooperativity (60). Free biER-a concentration (nM) Competitor (nM) (43, 64) .
Using the FP binding assay, the o,p'-DDT isomer of the pesticide DDT was found to have 4-10 times higher binding affinity for hrER-a than the p,p'-DDT isomer component. While this relationship between isomer and ER affinity is the same as found by others using MCF-7 or mouse ER (61,63), both isomers display higher affinity for the ER in the FP binding assay (Table 1 ). In the case of the estrogenic pesticide methoxychlor (12, 25) , this parent compound was found to have a much lower hrER-a RBA using the FP assay than its estrogenic metabolite HPTE. Furthermore, these ER binding values for methoxychlor and HPTE correspond closely to previous determinations (43, 63, 64) . The estrogenic pesticide kepone (10, 11, 24) had an hrER-a RBA value in the FP assay that is similar to the ER binding interactions reported from other laboratories (43, 63) . At the same time, the pesticide dieldrin was found to have only the extremely weak interaction with hrER-a that has been reported by others (66, 70 CRBA values prefaced were calculated from IC50 values that we estimated from the cited literature.
reported in Table 1 . The possible range of receptor purity obtained in these dissimilar preparations, as well as the fact that ER from distinct species may differ significantly in the ligand binding domain (73), may account for such differences. Even when the high purity and stability of the recombinant human ER used in the FP assay is taken into account, the extrapolation of receptor binding results from human to other species is undear. It is possible that using a purified ER preparation in this assay unduly simplifies the ligand-ER interaction, but FP assays are ideally suited for assessing the effects of added binding components. Second, when the FP binding assay's ability to evaluate receptor occupancy at true equilibrium conditions and at a relevant temperature is considered, it is not unexpected that RBA values obtained by FP might differ from those obtained using traditional 40C binding assays. It is possible that the relatively high ER RBA values obtained from the FP assay for some chemicals (e.g., the DDT isomers and BBP) are a reflection of this method's more realistic experimental conditions. At the same time, the observation that some estrogens displayed a weaker than expected affinity for ER in the FP assay (estrone, DES, and bisphenol A) may also be due to temperature or equilibrium condition effects. Finally, when considering industrial or environmental compounds that are difficult to obtain as pure samples (e.g., 4-tert-nonylphenol), differences in ER affinity between laboratories may be related to sample source. Taken together, the ER RBA values obtained in this study are within the range of determinations reported by other laboratories. Most importantly, the ER binding interactions determined with the FP binding assay in this study are similar to the evaluations of estrogen activity made for these same compounds using other in vitro methods (43, 61, 67, 68, 70 
